CoChat
Sign Up
PreprintCited by 258SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 98 of the 101 references it cites were found in a registry or an index.

A human coronavirus evolves antigenically to escape antibody immunity

Open access
Eguia, Rachel, Crawford, Katharine H. D., Stevens-Ayers, Terry, Kelnhofer-Millevolte, Laurel, Greninger, Alexander L., Englund, Janet A., Boeckh, Michael J., Bloom, Jesse D.·2020·PLoS Pathogens
DOI 10.1101/2020.12.17.423313PMC PMC8031418

Preprint — published as 10.1371/journal.ppat.1009453

Open this paper in CoChat — free accountOpen PDF

Abstract

There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these “future” viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers >1:100 do not detectably neutralize strains isolated 8–17 years later. The decreased neutralization of “future” viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.12.17.423313

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Spikes used in this study. (A) Phylogenetic tree of 229E spikes, with tips colored by the country from which the virus was isolated. The spikes used in the experiments are indicated with black text and square shapes. The tree is a maximum-likelihood inference with IQ-TREE [82] with a codon-substitution model and re-scaled with TreeTime [84] to position tips by to date of isolation. S1 Fig shows a tree with branch lengths proportional to divergence rather than time, and validates clock-like evolution. S2 Fig shows recombination does not substantially affect the phylogenetic placements of the spikes used in the experiments. (B) Protein sequence divergence of the spikes used in the experiments, computed over just the receptor-binding domain (RBD) or the full sequence. Divergence is the Levenshtein distance between the amino-acid sequences divided by the number of sites.
Fig 1 Spikes used in this study. (A) Phylogenetic tree of 229E spikes, with tips colored by the country from which the virus was isolated. The spikes used in the experiments are indicated with black text and square shapes. The tree is a maximum-likelihood inference with IQ-TREE [82] with a codon-substitution model and re-scaled with TreeTime [84] to position tips by to date of isolation. S1 Fig shows a tree with branch lengths proportional to divergence rather than time, and validates clock-like evolution. S2 Fig shows recombination does not substantially affect the phylogenetic placements of the spikes used in the experiments. (B) Protein sequence divergence of the spikes used in the experiments, computed over just the receptor-binding domain (RBD) or the full sequence. Divergence is the Levenshtein distance between the amino-acid sequences divided by the number of sites.CC BY · PubMed Central
Fig 2 The neutralizing activity of human sera is lower against “future” viruses than those that elicited the immunity. (A) Sera collected between 1985 and 1990 was tested in neutralization assays against spikes from viruses isolated between 1984 and 2016. Each plot facet is a different serum, and black points show its neutralizing titer against viruses from the indicated year. Blue shading indicates the portion of plotted timeframe during which the individual could have been infected prior to serum collection. The dotted gray horizontal line indicates the limit of detection (titer of 1:10). Plot titles give the year of serum collection, the individual’s age when the serum was collected, and the serum ID. (B) Plots like those in (A) but for sera collected between 1993 and 1995. (C) The fold change in neutralization titer against viruses isolated 8–9 or 16–17 years in the “future” relative to the virus isolated just before the serum was collected. Box plots show the median and interquartile range, and each point is the fold change for a single serum. For a few sera (triangles), the fold change is censored (as an upper bound) because the titer against the future virus was below the limit of detection.
Fig 2 The neutralizing activity of human sera is lower against “future” viruses than those that elicited the immunity. (A) Sera collected between 1985 and 1990 was tested in neutralization assays against spikes from viruses isolated between 1984 and 2016. Each plot facet is a different serum, and black points show its neutralizing titer against viruses from the indicated year. Blue shading indicates the portion of plotted timeframe during which the individual could have been infected prior to serum collection. The dotted gray horizontal line indicates the limit of detection (titer of 1:10). Plot titles give the year of serum collection, the individual’s age when the serum was collected, and the serum ID. (B) Plots like those in (A) but for sera collected between 1993 and 1995. (C) The fold change in neutralization titer against viruses isolated 8–9 or 16–17 years in the “future” relative to the virus isolated just before the serum was collected. Box plots show the median and interquartile range, and each point is the fold change for a single serum. For a few sera (triangles), the fold change is censored (as an upper bound) because the titer against the future virus was below the limit of detection.CC BY · PubMed Central
Fig 3 Neutralizing titers of sera collected in 2020 are higher against historical viruses that circulated during an individual’s lifetime than viruses isolated before the individual was born. As in Fig 2A and 2B, each plot facet is a different serum with the title giving the individual’s age and black points indicating the titer against spikes from viruses isolated in the indicated year. Blue shading represents the portion of the plotted timeframe during which the individual was alive: for adults this is the entire timeframe, but for children the left edge of the blue shading indicates the birth year.
Fig 3 Neutralizing titers of sera collected in 2020 are higher against historical viruses that circulated during an individual’s lifetime than viruses isolated before the individual was born. As in Fig 2A and 2B, each plot facet is a different serum with the title giving the individual’s age and black points indicating the titer against spikes from viruses isolated in the indicated year. Blue shading represents the portion of the plotted timeframe during which the individual was alive: for adults this is the entire timeframe, but for children the left edge of the blue shading indicates the birth year.CC BY · PubMed Central
Fig 4 Antigenic evolution is primarily due to changes in the spike’s receptor binding domain (RBD). (A) At top is a schematic of the 229E spike. Within the S1 subunit, the schematic indicates the N-terminal domain (NTD, also known as S1-A) and the RBD (also known as S1-B). The three loops in the RBD that bind the virus’s APN receptor are indicated [53]. Below the schematic is a plot of sequence variability across the alignment of 229E spikes in Fig 1A. Variability is quantified as the effective number of amino acids at a site [86], with a value of one indicating complete conservation and larger values indicating more sequence variability. (B) Site entropy mapped on 229E spike structure (PDB 6U7H, [53]). (C) Neutralizing titers of sera collected between 1985 and 1990 against either the full spike of “future” viruses or chimeras consisting of the 1984 spike containing the RBD from “future” viruses. The plot format and the black circles (full spike) are repeated from Fig 2A with the addition of the orange triangles showing the titers against the chimeric spikes.
Fig 4 Antigenic evolution is primarily due to changes in the spike’s receptor binding domain (RBD). (A) At top is a schematic of the 229E spike. Within the S1 subunit, the schematic indicates the N-terminal domain (NTD, also known as S1-A) and the RBD (also known as S1-B). The three loops in the RBD that bind the virus’s APN receptor are indicated [53]. Below the schematic is a plot of sequence variability across the alignment of 229E spikes in Fig 1A. Variability is quantified as the effective number of amino acids at a site [86], with a value of one indicating complete conservation and larger values indicating more sequence variability. (B) Site entropy mapped on 229E spike structure (PDB 6U7H, [53]). (C) Neutralizing titers of sera collected between 1985 and 1990 against either the full spike of “future” viruses or chimeras consisting of the 1984 spike containing the RBD from “future” viruses. The plot format and the black circles (full spike) are repeated from Fig 2A with the addition of the orange triangles showing the titers against the chimeric spikes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 6

  1. Crawford, K.H.D. , Dingens, A.S. , Eguia, R. , Wolf, C.R. , Wilcox, N. , Logue, J.K. , Shuey, K. , Casto, A.M. , Fiala, B. , Wrenn, S. , et al. (2020a). Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J. Infect. Dis. · DOI
  2. Kemp, S. (2020). Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion | medRxiv. BioRxiv.
  3. Kemp, S.A. , Collier, D.A. , Datir, R. , Gayed, S. , Jahun, A. , Hosmillo, M. , Ferreira, I. , Rees-Spear, C. , Mlcochova, P. , Lumb, I.U. , et al. (2020). Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. MedRxiv 2020.12.05.20241927.
  4. Lumley, S.F. , O’Donnell, D. , Stoesser, N.E. , Matthews, P.C. , Howarth, A. , Hatch, S.B. , Marsden, B.D. , Cox, S. , James, T. , Warren, F. , et al. (2020). Antibodies to SARS-CoV-2 are associated with protection against reinfection. MedRxiv 2020.11.18.20234369. · DOI
  5. Muñoz-Alía, M.Á. , Nace, R.A. , Zhang, L. , and Russell, S.J. (2020). Pathogenic measles viruses cannot evolve to bypass vaccine-induced neutralizing antibodies. BioRxiv 2020.10.22.351189. · DOI
  6. Thomson, E. (2020). The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity | bioRxiv. BioRxiv.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D.
Affiliations
  • Fred Hutch Cancer Center (US)
  • University of Washington (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Bloom, Jesse D.
ORCID
Venue
PLoS Pathogens
Publisher
openRxiv
Published
2020-12-18
Volume
17
Issue
4
Pages
e1009453-e1009453
ISSN
1553-7366 (ISSN-L)
DOI
10.1101/2020.12.17.423313
PMC
PMC8031418
OpenAlex
W3144378969
Cited by
258
References
101
Citations by year
2026: 7 · 2025: 21 · 2024: 11 · 2023: 33 · 2022: 69 · 2021: 103 · 2020: 2
FWCI
17.09
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Howard Hughes Medical Institute
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Fred Hutchinson Cancer Research Center
  • Regeneron Pharmaceuticals
  • Moderna
  • National Institutes of Health
  • Sanofi Pasteur
  • National Institute of General Medical Sciences (T32GM007266)
  • National Institute of Allergy and Infectious Diseases (R01AI127893, F30AI149928, R01AI141707)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
HCoV-229E, antigenic evolution, antibody escape, neutralizing antibodies, spike protein, receptor binding domain, coronavirus evolution
MeSH terms
SARS-CoV-2, Antibodies, Viral, Humans, Coronavirus 229E, Human, Immune Evasion, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review